Christopher Brooke - Net Worth and Insider Trading

Christopher Brooke Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Christopher Brooke owns 1 companies in total, including Aytu BioPharma Inc (AYTU) .

Click here to see the complete history of Christopher Brooke’s form 4 insider trades.

Insider Ownership Summary of Christopher Brooke

Ticker Comapny Transaction Date Type of Owner
AYTU Aytu BioPharma Inc 2023-08-11 Chief Operating Officer

Christopher Brooke Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Christopher Brooke Ownership Network

Ownership Network List of Christopher Brooke

No Data

Ownership Network Relation of Christopher Brooke

Insider Network Chart

Christopher Brooke Owned Company Details

What does Aytu BioPharma Inc do?

Who are the key executives at Aytu BioPharma Inc?

Christopher Brooke is the Chief Operating Officer of Aytu BioPharma Inc. Other key executives at Aytu BioPharma Inc include Chief Business Officer Jarrett Disbrow , Chief Financial Officer Mark K Oki , and director & Chief Executive Officer Joshua R. Disbrow .

Aytu BioPharma Inc (AYTU) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aytu BioPharma Inc (AYTU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aytu BioPharma Inc (AYTU) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aytu BioPharma Inc (AYTU)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Aytu BioPharma Inc Insider Transactions

No Available Data

Christopher Brooke Mailing Address

Above is the net worth, insider trading, and ownership report for Christopher Brooke. You might contact Christopher Brooke via mailing address: C/o Aytu Biopharma, Inc., 373 Inverness Parkway, Suite 206, Englewood Co 80112.

Discussions on Christopher Brooke

No discussions yet.